Abstract: A system and method of optical coherence tomography includes defining a suspect region-of-interest (SROI) for a suspect lesion in a first OCT B-scan image, defining a healthy region-of-interest (HROI) near the suspect lesion in a second OCT B-scan image, extracting optical properties from the SROI and from the HROI, obtaining an averaged A-line in the SROI and in the HROI, creating a set of normalized optical radiomic features from the averaged A-line in the SROI and in the HROI, and evaluating the set of normalized optical radiomic features to distinguish whether the suspect lesion is consistent with melanoma.

Abstract: A manufacturing facility for assembling a jacket structure 3 comprising a number of subcomponents 10, said subcomponents 10 including a prefabricated brace 12 and a pair of prefabricated legs 30, 30?, wherein the manufacturing facility comprises a number of first supports 20 for supporting each of the prefabricated legs 30,30?, a number of second supports 40 for supporting the prefabricated brace 12 and a welding unit for welding the prefabricated brace 12 to the prefabricated legs 30,30?.

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum), The invention is based on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.

Abstract: A network function virtualization (NFV) platform can support hybrid and elastic scaling and recovery services. In one example, a system can deploy a cloud virtual network function manager (VNFM) and one or more cloud virtual network functions (VNFs) on a cloud. The system can monitor, via the cloud VNFM, a local VNFM on a local network, the cloud VNFM, and/or the one or more cloud VNFs. Based on the monitoring, the system can determine, via the cloud VNFM, a respective status of the local VNFM, the cloud VNFM, and/or the one or more cloud VNFs. Based on the respective status of the local VNFM, the cloud VNFM, and/or the one or more cloud VNFs, the system can then scale, via the cloud VNFM, the local VNFM, the cloud VNFM, and/or the one or more cloud VNFs.

Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

Abstract: The disclosure provides an implantable medical device comprising a material capture element, which has a generally closed conical deployed shape and a narrow end disposed at or proximate the first end of the device. The material capture element includes a wide end facing the second end of the device, the material capture element having a zone of wider radial dimension which provides a first vessel contact site. A plurality of wire tethers are coupled to the wide end and extend to the second end. The wire tethers define a substantially open passageway for blood and provide a second vessel contact site. The first and second contact sites are spaced longitudinally from one another to provide stability. A first retrieval element is disposed at the first end and coupled to the narrow end, while a second retrieval element is disposed at the second end and coupled to the wire tethers.

Abstract: A network function virtualization (NFV) platform can support virtual network functions (VNFs) whose behavior can change during their lifecycles. For example, a VNF manager of the NFV platform can receive a request to update a condition of a VNF and/or an action to perform upon satisfaction of the condition. Based on the condition and action, the VNF manager can create or store a lifecycle management policy in an extensible lifecycle management model associated with the virtual network function. Based on the lifecycle management policy, the VNF manager can monitor the virtual network function to detect satisfaction of the condition and, in response to detecting satisfaction of the condition, the VNF manager can perform the action associated with the lifecycle management policy.

Abstract: The invention relates to a tool for manual or especially automatic removal of tenderloins from half-carcasses of slaughtered animals. The tool comprises a circular knife blade, a blade housing supporting the knife blade, and a movable knife blade protector. The tool is connected to a motor capable of driving the knife blade. A tenderloin is partly cut free with the knife, the knife blade protector is activated to protect the knife blade and the tool is used to pull the tenderloin free from the half-carcass without damaging the tenderloin with the knife. The tool can be arranged on a robot and can be used for automatic removal of tenderloins from half-carcasses at slaughterhouses.

Abstract: The invention relates to a tool for manual or especially automatic removal of tenderloins from half-carcasses of slaughtered animals. The tool comprises a circular knife blade, a blade housing supporting the knife blade, and a movable knife blade protector. The tool is connected to a motor capable of driving the knife blade. A tenderloin is partly cut free with the knife, the knife blade protector is activated to protect the knife blade and the tool is used to pull the tenderloin free from the half-carcass without damaging the tenderloin with the knife. The tool can be arranged on a robot and can be used for automatic removal of tenderloins from half-carcasses at slaughterhouses.

Abstract: A magnetic guidance system (20) for guiding a guidewire (70) or other elongate medical device includes a magnet unit (20) disposed in one implementation adjacent a head end of a patient table (30). The magnet unit is disposed on a magnet support which enables the magnet unit (20) to move in a periodic motion substantially around a single plane. The preferred motion is a rotary motion about a patient's head, which creates a repetitive repulsive force at the distal end of the medical device, causing the distal end of the medical device to move in different directions within the patient's vasculature, useful in assisting the guidance of the medical device through tortuous vessel structures. The repetitive alternating medical field makes guidance of a medical device within a patient's vasculature a relatively simple task.

Abstract: A thrombus removal apparatus (10) includes a catheter (12) having at its distal end (14) a solenoid coil section (16) within which there is disposed a piercing element (20) made of electromagnetic material. Within the solenoid coil section (16) there is provided a solenoid coil (26) which can be powered to generate an electromagnetic field which causes the piercing element (20) to reciprocate into and out of the coil section (16), in practice to pierce into and fragment a thrombus disposed in a patient's vessel. An aspiration unit may be provided for aspirating thrombus fragments into the assembly (10) for removal from the patient's vasculature. The apparatus (10) is able to remove dense thrombus material from within a patient, which cannot be otherwise removed by means of thrombolytic agents.

Abstract: An armature assembly comprising an armature body and a number of armature ring segments mounted on the armature body, wherein the armature assembly comprises a number of insertion interface elements and a number of complementary receiving interface elements for mounting an armature ring segment onto the armature body; whereby an insertion interface element is realized to engage with a complementary receiving interface element in a direction essentially parallel to a rotation axis of the armature; and wherein an insertion interface element is formed as an integral part of the armature body or as an integral part of an armature ring segment. A method of assembling an armature is also described, and a wind turbine comprising such an armature assembly is provided.

Abstract: The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1) which are among the most immunodominant M. tuberculosis (MTB) antigens.

Abstract: A measurement device for measuring voltages along a linear array of voltage sources, such as a fuel cell stack, includes at least one movable voltage probe that measures voltage transitions along an array element. The measured voltage is used to determine a distance of travel of the at least one voltage probe along the fuel cell stack from the speed of the probe and the timing of the transitions.

Abstract: An implantable medical device includes a body member, which may be a graft tube, is provided with a plurality of magnetic elements disposed in opposing sets and arranged with opposing magnetic polarities. The magnetic elements create repulsive forces which open the implantable medical device, providing an alternative to a conventional implantable medical device which is kept open by mechanical forces.

Abstract: The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1) which are among the most immunodominant M. tuberculosis (MTB) antigens.

Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum). The invention is base on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.

Abstract: Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4+T cells expressing high levels of IFN-?, TNF-?, and IL-2. This in turn led to significant protection against infection with M. tuberculosis in the mouse aerosol challenge model of tuberculosis. Both the immunogenicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5 ?g, as well as 15 ?g, did not induce significant protection against M. tuberculosis, reducing the dose to 0.5 ?g increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the IC31® adjuvant, with the specified antigen dose, can induce a strong protective Th1 response against M. tuberculosis.